Development of predictive pharmacokinetic simulation models for drug discovery

Journal of Controlled Release

Volumn 65, Issue 1-2, 2000, Pages 55-62

  Norris, D A ^a   Leesman, G D ^a   Sinko, P J ^a,b   Grass, G M ^a  

^a Trega Biosciences   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Bioavailability; Dogs; Ganciclovir; Humans; Simulation models

Indexed keywords

ATENOLOL; GANCICLOVIR; NAPROXEN;

ABSORPTION; ARTICLE; COMPUTER SIMULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SOLUBILITY; HUMAN; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; DIGESTIVE SYSTEM; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GANCICLOVIR; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 0033999569     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00232-1     Document Type: Article

References (29)

1. Prentis R.A., Lis Y., Walker S.R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25:1988;387-396.
2. Kennedy T. Managing the drug discovery/development interface. DDT. 2:1997;436-444.
3. Dressman J.B., Amidon G.L., Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J. Pham. Sci. 74:1985;588-589.
4. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res Commun. 175:1991;880-885.
5. Amidon G.L., Sinko P., Fleisher D. Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 5:1988;651-654.
6. Polli J.E., Crison J.R., Amidon G.L. Novel approach to the analysis of in vitro-in vivo relationships [published erratum appears in J Pharm Sci 1997 Feb;86(2):268]. J. Pharm. Sci. 85:1996;753-760.
7. Ishii K., Katayama Y., Itai S., Ito Y., Hayashi H. In vitro dissolution tests corresponding to the in vivo dissolution of clarithromycin tablets in the stomach and intestine. Chem. Pharm. Bull. (Tokyo). 43:1995;1943-1948.
8. Dressman J.B., Fleisher D. Mixing-tank model for predicting dissolution rate control of oral absorption. J. 75:(2):1986;109-109.
9. Dunne A., O'Hara T., Devane J. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption [In Process Citation]. Stat. Med. 18:1999;1865-1876.
10. Ginski M.J., Polli J.E. Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system. Int. J. Pharm. 177:1999;117-125.
11. Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15:1998;11-22.
12. Sietsema W.K. The absolute oral bioavailability of selected drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 27:1989;179-211.
13. Grass G.M. Simulation models to predict oral drug absorption from in vitro data. Adv. Drug Delivery Rev. 23:1997;199-219.
14. Yu L.X., Amidon G.L. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur. J. Pharm. Biopharm. 45:1998;199-203.
15. Gillespie W.R. Convolution-based approaches for in vivo-in vitro correlation modeling. Adv. Exp. Med. Biol. 423:1997;53-65.
16. Kaus L.C., Gillespie W.R., Hussain A.S., Amidon G.L. The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the- curve of drugs with different gastrointestinal permeabilities. Pharm. Res. 16:1999;272-280.
17. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:1995;413-420.
18. Martin J.C., Dvorak C.A., Smee D.F., Matthews T.R., Verheyden J.P. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med. Chem. 26:1983;759-761.
19. Smee D.F., Martin J.C., Verheyden J.P., Matthews T.R. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2- propoxymethyl)guanine. Antimicrob. Agents Chemother. 23:1983;676-682.
20. Anderson R.D., Griffy K.G., Jung D., Dorr A., Hulse J.D., Smith R.B. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin. Ther. 17:1995;425-432.
21. Spector S.A., Busch D.F., Follansbee S., Squires K., Lalezari J.P., Jacobson M.A., Connor J.D., Jung D., Shadman A., Mastre B. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. J. Infect. Dis. 171:1995;1431-1437.
22. Lavelle J., Follansbee S., Trapnell C.B., Buhles W.C., Griffy K.G., Jung D., Dorr A., Connor J. Effect of food on the relative bioavailability of oral ganciclovir. J. Clin. Pharmacol. 36:1996;238-241.
23. Benjamin E.J., Firestone B.A., Bergstrom R., Fass M., Massey I., Tsina I., Lin Y.Y. Selection of a derivative of the antiviral agent 9-[(1,3-dihydroxy-2- propoxy)-methyl]guanine (DHPG) with improved oral absorption. Pharm. Res. 4:1987;120-125.
24. Jezyk N., Rubas W., Grass G.M. Permeability characteristics of various intestinal regions of rabbit, dog, and monkey. Pharm. Res. 9:1992;1580-1586.
25. Budavari S., O'Neil M.J., Smith A., Heckelman P.E., Kinneary J.F. 12th Edition The Merck Index. 1996;Merck & Co., Inc, Whitehouse Station, NJ.
26. Physician's Desk Reference. 52nd Edition :1998;Medical Economics Company, Inc.
27. McAinsh J., Holmes B.F. Pharmacokinetic studies with atenolol in the dog. Biopharm. Drug Dispos. 4:1983;249-261.
28. Anderson R.D., Griffy K.G., Jung D., Dorr A., Hulse J.D., Smith R.B. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin. Ther. 17:1995;425-432.
29. Frey H.H., Rieh B. Pharmacokinetics of naproxen in the dog. Am. J. Vet. Res. 42:1981;1615-1617.